प्रत्यारोपण प्रौद्योगिकी एवं अनुसंधान

Clinical Utility of Peripheral Blood Gene Expression Profiling of Kidney Transplant Recipients to Assess the Need for Surveillance Biopsies in Subjects with Stable Renal Function

Abstract

Martin Roy First, Thomas Whisenant, John J Friedewald, Peter Lewis, Stan Rose, Darren Lee, Deirdre Pierry, Sunil M Kurian, Terri Gelbart and Michael M Abecassis

Background: TruGraf is a blood test that measures gene expression signatures in kidney transplant recipients, providing information on adequacy of immunosuppression. Signatures derived from peripheral blood using DNA microarrays have been internally and externally validated in two populations of transplant recipients: (i) patients designated as TX (“Transplant eXcellence”) - stable serum creatinine and normal biopsy, indicative of immune quiescence, and (ii) patients designated as not-TX (renal dysfunction and/or histological abnormalities). The test is intended for use in subjects with stable renal function as an alternative to protocol biopsies.
Methodology: Simultaneous blood tests and transplant biopsies were performed in 169 patients. The molecular laboratory was blinded to renal function and biopsy results.
Results: Biopsy-confirmed clinical phenotype was TX (105 cases), not-TX (64). Renal function was stable in 125 subjects (105 TX, 20 not-TX). Positive predictive value of TruGraf for detecting TX was 86% and 105/125 (84%) had a normal biopsy result.
Significance of study: In subjects with stable renal function, TruGraf blood test result of TX corresponded to biopsy findings in 88% of cases. Results indicate that had the blood test been run in place of surveillance biopsies, 107/125 (86%) of patients with stable renal function may have avoided an invasive biopsy and 92/105 (88%) of these patients with biopsy-confirmed TX may have avoided a biopsy for a negative result.